Where Arthrosamid sits in the treatment ladder

For many patients with knee osteoarthritis, there comes a point at which the standard conservative measures have been genuinely exhausted. Physiotherapy has run its course, analgesics are managing rather than resolving the pain, weight has been addressed, and at least one short-acting injection — corticosteroid or hyaluronic acid — has offered only temporary benefit. The symptoms remain limiting. Yet the knee, on imaging and clinical assessment, does not yet meet the threshold for joint replacement, or the patient is not ready for that step. It is precisely this window that Arthrosamid is designed to address.

Arthrosamid is not a first-line treatment, and it should not be presented as one. Its place in a staged pathway comes after conservative management has been completed — not bypassed. Nor is it interchangeable with the injections that typically precede it. Where corticosteroids act on acute inflammation and hyaluronic acid supplements joint fluid, Arthrosamid works differently: once injected, the polyacrylamide hydrogel adheres to the synovial membrane and integrates structurally, bulking it up rather than simply supplementing the joint environment. That distinction matters clinically, because it means the treatment occupies a different mechanism and a different duration profile.

Importantly, the evidence base supports its use in knee osteoarthritis specifically — not in undifferentiated knee pain or in inflammatory arthropathies such as rheumatoid or psoriatic arthritis, where the underlying pathology is incompatible with this approach. The treatment is a single injection targeting a defined condition, within a defined part of the treatment journey.

The patient profile most likely to benefit

The clearest picture of who responds comes from a 2025 observational cohort of 269 patients and 314 knees followed over 24 months — currently the largest published dataset to apply multivariate analysis specifically to this question. Four independent factors were associated with reaching a clinically meaningful improvement across all three WOMAC domains: older age, a lower Kellgren–Lawrence grade, absence of diabetes, and bilateral rather than unilateral knee OA.

These are exploratory associations from an observational study with no control group, not validated responder rules that can predict outcome for any individual patient. But they represent the strongest direct evidence currently available on who benefits, and they carry genuine clinical weight when reviewing a referral.

Translated into the consulting room, the picture that emerges is a patient with confirmed osteoarthritis on recent imaging — ideally an X-ray or MRI within the preceding 12 months — whose structural changes fall in the mild-to-moderate range (KL grade II or III). Patients at the more severe end of that spectrum did respond in the cohort, but they were significantly more likely to require total knee replacement within the study period: 49 of the 269 patients proceeded to replacement, and higher KL grade was a strong predictor of that progression (p<0.001). That figure is not a reason to withhold the treatment from every patient with moderate-to-advanced disease, but it is a reason to have a frank conversation about what the injection is and is not likely to achieve.

Non-diabetic status and bilateral involvement also independently predicted response. The mechanism behind those associations is not yet fully established, but both signal that systemic metabolic factors and the pattern of disease matter alongside radiographic severity.

Critically, imaging confirms the diagnosis — that the pain is driven by osteoarthritis rather than another pathology — before any injection decision is made. Appropriate candidates also understand from the outset that Arthrosamid targets symptoms, not structural repair: it does not regenerate cartilage, and it has not been shown to delay replacement.

When Arthrosamid is not the right path

Recommending against Arthrosamid is, in itself, a clinical decision — and one that deserves the same rigour as recommending for it. The most important signal is structural disease severity. As the 24-month cohort demonstrates, patients with higher Kellgren–Lawrence grades were significantly more likely to require total knee replacement within the study period (p<0.001). When a knee is already on that trajectory, an injection-based intervention risks deferring surgery without meaningfully altering its timing — a poor trade for the patient.

Advanced structural damage is therefore not simply an eligibility filter. It is a clinical signal that the disease has progressed to a point where surgical planning, rather than further joint-preservation manoeuvres, is the appropriate conversation to be having. Recommending a patient towards orthopaedic assessment for replacement at the right moment is expert guidance, not a failure of the treatment.

Beyond structural considerations, a number of absolute contraindications apply. Active local or systemic infection excludes treatment entirely, given the permanent, non-biodegradable nature of the implant — infection involving a device that integrates with the synovial membrane carries risks that are more serious than those associated with a temporary or absorbable agent. Inflammatory arthropathies, pregnancy and breastfeeding, age under 18, bleeding disorders, and heavy anticoagulation all preclude injection. So do recent knee surgery or arthroscopy within six months, and the presence of an existing knee implant.

These are not marginal concerns buried in a consent form. They are part of every pre-injection assessment, and identifying them early — steering the patient away from an unsuitable procedure and towards the right one — is where clinical judgment matters most.

Realistic outcomes: what the evidence actually shows

Roughly one in three appropriately selected patients who receive Arthrosamid does not achieve a clinically meaningful response. That figure — drawn from a 12-month open-label study in which 62.2% of participants met OMERACT-OARSI responder criteria at 52 weeks — is the most patient-relevant single number in the evidence base, and it belongs at the front of any outcome conversation rather than in the small print.

For those who do respond, the duration of benefit is more substantive than the alternatives many patients will have already tried. A comparative retrospective cohort of 150 patients found that hyaluronic acid and corticosteroid groups returned to near-baseline pain scores by 12 months while iPAAG remained stable. That is not a formal claim of superiority — the difference from HA at 12 months did not reach statistical significance — but it does contextualise where Arthrosamid sits for a patient whose earlier short-acting injection wore off after a few months.

The longer-term picture is supported by two independent 5-year studies. An RCT extension (58 completers) reported a mean WOMAC pain improvement of −16.2 points (p<0.0001) at year five, with no adverse events attributable to the device during the extension period. A separate prospective open-label study (27 completers) found a WOMAC pain reduction of −14.6 points (p=0.0002) sustained across the same timeframe.

Both figures carry a caveat that is honest rather than deflating: these are five-year completers drawn from studies that began with considerably larger cohorts. Patients who persist through five years of follow-up are a self-selected subgroup — likely those with good responses and no significant complications. Durability at that level is plausible and clinically encouraging; it cannot be presented as a certainty for the broader population of patients considering the treatment.

The permanent implant: what patients need to know before deciding

The conversation that precedes an Arthrosamid injection is necessarily different from the one before a corticosteroid or hyaluronic acid top-up — and what makes it different is the permanence of the implant.

That permanence has already been established as a factor in excluding certain patients. In the consent setting, the consideration runs further: if infection develops around a device that integrates with the synovial membrane and will not dissolve, management may require joint washout rather than antibiotic treatment alone. That is a materially different clinical situation from a complication following an absorbable injection, and it informs both pre-procedure assessment and the monitoring guidance a patient receives afterwards.

On effusion: post-injection joint swelling is the most commonly reported complication, but its true rate is not fully captured in the published literature. Some studies recorded patient-reported 'sensation of distension' rather than clinically assessed effusion, meaning the genuine inflammatory complication rate is likely higher than the figures suggest. Patients should be told this plainly — and given clear guidance on what changes to look for and when to seek review — rather than being left with only the headline numbers.

Weighed against those considerations, the permanence of the implant is also the source of its durability advantage. A single injection that maintains meaningful symptom relief over years represents a genuine clinical gain for the right patient. The decision to proceed is therefore not a choice about whether to accept an uncomplicated, short-acting procedure. It is a considered judgement about whether the profile of a permanent intra-articular implant — its benefits and its specific risk character — represents the right trade-off for this person, at this point in their disease.

How the selection decision is made in practice

No checklist produces the answer. Whether Arthrosamid belongs in a patient's care plan depends on weighing structural severity against symptom burden, the completeness of prior treatment against what the patient has actually tolerated, comorbidities such as diabetes that the evidence identifies as outcome predictors, and the patient's own understanding of what a permanent implant involves.

The interaction between those variables is what makes the assessment genuinely demanding. A patient with Kellgren-Lawrence grade III OA and persistent pain after physiotherapy and earlier injections might appear to fit the profile — but if diabetes is poorly controlled, the risk-benefit calculation shifts materially. If imaging suggests rapid disease progression, the more clinically honest conversation may concern timing a knee replacement rather than deferring it. Bilateral involvement, older age, and lower structural grade all independently increase the probability of a meaningful response; none of those factors operates in isolation from the rest of the clinical picture.

Reaching that judgment draws on more than published selection criteria. It requires interpreting imaging in the context of the individual patient, distinguishing treatments that have been genuinely exhausted from those only nominally attempted, and holding a frank discussion about what symptom management — not structural repair — means over a five-to-ten-year horizon. Professor Paul Lee's 2022 paper documenting bone marrow lesion reduction following a single iPAAG injection in advanced knee OA reflects that kind of clinical engagement: not adoption of a procedure, but direct interrogation of what it does at a tissue level.

For the patient asking whether Arthrosamid is right for them, the answer emerges from that process. The relevant question is not only whether they clear a threshold, but whether the profile of this specific permanent intra-articular implant — its probable duration of benefit, its risk character, and its place within their broader disease trajectory — represents the right trade-off at this point in their condition.

1. [1] Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. (2025). https://doi.org/10.1016/j.jcot.2025.103136 https://doi.org/10.1016/j.jcot.2025.103136
2. [2] Effectiveness and safety of polyacrylamide hydrogel injection for knee osteoarthritis: results from a 12-month follow up of an open-label study. (2024). https://doi.org/10.1186/s13018-024-04756-2 https://doi.org/10.1186/s13018-024-04756-2
3. [3] A prospective, open-label, clinical investigation of a single intra-articular polyacrylamide hydrogel injection: a 5-year extension study. (2025). https://doi.org/10.1186/s13018-025-06526-0 https://doi.org/10.1186/s13018-025-06526-0
4. [4] Sustained symptom relief and safety over five years following a single intra-articular injection of 2.5% polyacrylamide hydrogel in patients with knee osteoarthritis. (2025). https://doi.org/10.55563/clinexprheumatol/bsper8 https://doi.org/10.55563/clinexprheumatol/bsper8
5. [5] Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. (2025). https://doi.org/10.1097/MD.0000000000044655 https://doi.org/10.1097/MD.0000000000044655